



**Submitted electronically via email**

January 12, 2022

Attn: MoIDX  
Palmetto GBA  
18 Technology Circle  
Columbia, SC 29203

**Re: LCD for thyroid nodule molecular biomarkers**

Dear MoIDX medical directors,

Thank you for considering our request for an LCD concerning molecular biomarkers for decision making in thyroid nodules. Veracyte has been an industry leader in thyroid nodule and thyroid cancer molecular diagnostics, and continues to advance the field. We have a portfolio of products, including those that have been widely embraced by guidelines and the treatment community, and products we are continuing to develop.

Veracyte previously submitted a coverage request specifically for Afirma MTC. However, given MoIDX's interest in foundational over product specific LCDs, we wish to follow-up our previous submission with a foundational LCD regarding thyroid nodule classifiers more broadly.

Please do not hesitate to contact us if you have any questions.

Sincerely,

A handwritten signature in dark ink, appearing to read "Paul Gerrard", written over a light blue horizontal line.

Paul Gerrard, MD

Medical Director of Managed Care and Government Accounts